Evidence map›Paper›PMID 37477952›Full record

ArticleThe Biochemical journal2023

SUFU promotes GLI activity in a Hedgehog-independent manner in pancreatic cancer.

Brooke D Paradise, Vladimir G Gainullin, Luciana L Almada, Ashley N Sigafoos, Sandhya Sen, Renzo E Vera, Glancis Luzeena Raja Arul, Murat Toruner, David R Pease, Alina L Gonzalez and 3 more

Open access · hybridAbstract read
In one paragraph

Article in The Biochemical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 3 countries.

Brooke D ParadiseSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, U.S.A.
Vladimir G GainullinSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, U.S.A.
Luciana L AlmadaSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, U.S.A.
Ashley N SigafoosSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, U.S.A.
Sandhya SenSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, U.S.A.
Renzo E VeraSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, U.S.A.
Glancis Luzeena Raja ArulSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, U.S.A.ORCID 0000-0002-7672-8597
Murat TorunerSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, U.S.A.
David R PeaseSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, U.S.A.
Alina L GonzalezFacultad de Ciencias Exactas y Naturales, Instituto de Ciencias de la Tierra y Ambientales de La Pampa (INCITAP), Universidad Nacional de La Pampa - Consejo Nacional de Investigaciones Científicas y Técnicas (UNLPam-CONICET), La Pampa 6300, Argentina.
Fatima M MentucciDepartment of Pharmacy, University of Salerno, Salerno 84084, Italy.
Daniel H GrassoInstituto de Estudios de la Inmunidad Humoral (IDEHU), Escuela de Farmacia y Bioquimica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires 1113, Argentina.
Martin E Fernandez-ZapicoSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, U.S.A.ORCID 0000-0002-8089-3907
Mayo Clinic · USUniversity of Salerno · IT

Funding

Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
Mechanism of Pancreatic CarcinogenesisR01CA136526 · NCI · MAYO CLINIC ROCHESTER · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO · 2009 to 2019
$3.0M
New Therapuetics for Pancreatic CancerR01CA265050 · NCI · MAYO CLINIC ROCHESTER · PI Mitesh Borad, Martin Ernesto Fernandez-Zapico · 2022 to 2026
$3.0M
NCI NIH HHS P50 CA102701NCI NIH HHS R01 CA136526NCI NIH HHS R01 CA265050NIDDK NIH HHS P30 DK084567
6 · The paper itself

Abstract

Aberrant activation of the Hedgehog (Hh) signaling pathway, through which the GLI family of transcription factors (TF) is stimulated, is commonly observed in cancer cells. One well-established mechanism of this increased activity is through the inactivation of Suppressor of Fused (SUFU), a negative regulator of the Hh pathway. Relief from negative regulation by SUFU facilitates GLI activity and induction of target gene expression. Here, we demonstrate a novel role for SUFU as a promoter of GLI activity in pancreatic ductal adenocarcinoma (PDAC). In non-ciliated PDAC cells unresponsive to Smoothened agonism, SUFU overexpression increases GLI transcriptional activity. Conversely, knockdown (KD) of SUFU reduces the activity of GLI in PDAC cells. Through array PCR analysis of GLI target genes, we identified B-cell lymphoma 2 (BCL2) among the top candidates down-regulated by SUFU KD. We demonstrate that SUFU KD results in reduced PDAC cell viability, and overexpression of BCL2 partially rescues the effect of reduced cell viability by SUFU KD. Further analysis using as a model GLI1, a major TF activator of the GLI family in PDAC cells, shows the interaction of SUFU and GLI1 in the nucleus through previously characterized domains. Chromatin immunoprecipitation (ChIP) assay shows the binding of both SUFU and GLI1 at the promoter of BCL2 in PDAC cells. Finally, we demonstrate that SUFU promotes GLI1 activity without affecting its protein stability. Through our findings, we propose a novel role of SUFU as a positive regulator of GLI1 in PDAC, adding a new mechanism of Hh/GLI signaling pathway regulation in cancer cells.

Indexed as

Pancreatic NeoplasmsRepressor ProteinsHedgehog ProteinsHumansProto-Oncogene Proteins c-bcl-2Transcription FactorsZinc Finger Protein GLI1Hedgehog ProteinsProto-Oncogene Proteins c-bcl-2Repressor ProteinsSUFU protein, humanTranscription FactorsZinc Finger Protein GLI1BCL2cell survivalGLI1pancreatic cancerSUFU

Identifiers

PMID37477952
PMCPMC11973541
OpenAlexW4384922482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.